Drug Profile
Interleukin-2 liposomal
Alternative Names: IL-2 liposomal; Interleukin-2-liposomal - OncoTherapeutics; L-IL-2; Liposomal interleukin-2; Liposomal-IL-2; Liposome-encapsulated IL-2; Liposome-encapsulated interleukin-2; OncoLipin 2; OTx 287Latest Information Update: 28 Oct 2021
Price :
$50
*
At a glance
- Originator University of Minnesota
- Developer Biomira USA; Oncodigm BioPharma
- Class Adjuvants; Antineoplastics; Immunotherapies; Interleukins; Lymphokines
- Mechanism of Action Immunostimulants; Interleukin 2 stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 06 Feb 2017 Discontinued - Phase-II for Cancer in USA (Inhalation)
- 22 Jul 2005 Interleukin-2 liposomal is available for licensing outside of North America (http://www.biomira.com)
- 24 May 2004 Oncodigm BioPharma is developing liposomal interleukin-2